Bluejay Diagnostics Tops 545-Patient Enrollment and Secures Capacity for 10M Test Cartridges
Bluejay Diagnostics enrolled 545 patients in its SYMON II IL-6 monitoring study, reaching over 72% of its 750-patient target and exceeding initial expectations under approved IRB protocols. The company advanced manufacturing readiness by completing cartridge characterization for U.S. production, securing antibody capacity for over 10 million test cartridges, and initiating technology transfer toward commercialization in 2026.
1. Clinical Enrollment Progress
Bluejay Diagnostics has enrolled 545 of the targeted 750 patients in its SYMON II multicenter IL-6 monitoring study, surpassing initial expectations under approved IRB protocols. Enrollment across all participating sites enhances dataset scale and diversity, reducing execution risk and paving the way for data analysis and regulatory discussions.
2. Manufacturing Readiness Advances
Manufacturing readiness efforts advanced with completion of cartridge characterization for U.S. commercial production and monoclonal and polyclonal antibody manufacturing sufficient for over 10 million test cartridges. Ongoing fabrication and validation of cartridge components and material substitution evaluations aim to improve cost efficiency and consistency ahead of FDA submission.
3. Next Steps Toward Commercialization
Technology transfer activities are proceeding without a single point of failure, supported by parallel execution strategies to mitigate timing and scale-up risks. Entering 2026 with reduced clinical risk and strengthened operational capabilities, the company now focuses on data analysis, regulatory engagement, and commercialization preparedness.